Axer-Siegel Ruth, Ehrlich Rita, Weinberger Dov, Rosenblatt Irit, Shani Ludmila, Yassur Yuval, Priel Ethan, Kramer Michal
Department of Ophthalmology, Rabin Medical Center, Beilinson Campus, Petah Tiqva, Israel.
Am J Ophthalmol. 2004 Oct;138(4):602-7. doi: 10.1016/j.ajo.2004.05.074.
To evaluate the visual outcome of patients with myopic subfoveal choroidal neovascularization (CNV) given photodynamic therapy (PDT) in a clinical setting, and to identify potential relation between the visual outcome and the age at treatment.
Interventional case series.
Retrospective comparative study.
Outpatient ophthalmology clinic.
Twenty-nine consecutive patients (30 eyes) with subfoveal CNV caused by pathologic myopia who were treated with verteporfin PDT from January 2000 to May 2003.
All the patients received verteporfin PDT and were followed clinically and with fluorescein angiography (FA). Review of the medical records and angiograms was performed. Patients were divided into two groups by age, using the median age (60 years) as the cutoff.
Visual acuity (VA) at the end of follow-up in the older-patient group compared with the younger-patient group.
The mean age was 63.1 years. Mean follow-up was 11.5 months. Patients received a mean of 3.48 treatments. Mean VA improved in the younger group from 0.63 to 0.39 logMAR (P = .02, paired t test) and deteriorated in the older group from 0.71 to 0.99 logMAR (P = .03, paired t test). In the whole cohort, 33% of eyes lost 3 or more lines of Snellen best-corrected VA; in the older age group, 50% of eyes lost 3 or more lines, whereas in the younger age group, only 8% of eyes did so (P = .024, Fisher's exact test).
In our consecutive case series, visual prognosis of myopic CNV after PDT was found to be influenced by age at treatment.
在临床环境中评估接受光动力疗法(PDT)的近视性黄斑下脉络膜新生血管(CNV)患者的视力转归,并确定视力转归与治疗时年龄之间的潜在关系。
干预性病例系列。
回顾性对照研究。
门诊眼科诊所。
2000年1月至2003年5月期间连续29例(30只眼)因病理性近视导致黄斑下CNV并接受维替泊芬PDT治疗的患者。
所有患者均接受维替泊芬PDT治疗,并进行临床随访及荧光素血管造影(FA)检查。对病历和血管造影片进行回顾。以年龄中位数(60岁)为界,将患者按年龄分为两组。
比较老年患者组与年轻患者组随访结束时的视力(VA)。
平均年龄为63.1岁。平均随访时间为11.5个月。患者平均接受3.48次治疗。年轻组平均VA从0.63 logMAR提高到0.39 logMAR(配对t检验,P = 0.02),而老年组从0.71 logMAR恶化到0.99 logMAR(配对t检验,P = 0.03)。在整个队列中,33%的眼最佳矫正视力(Snellen视力表)下降3行或更多;在老年组中,50%的眼下降3行或更多,而在年轻组中,只有8%的眼如此(Fisher精确检验,P = 0.02)。
在我们的连续病例系列中,发现PDT治疗后近视性CNV的视力预后受治疗时年龄的影响。